1
|
Palanco AC, Lacorte Singulani JD, Costa-Orlandi CB, Gullo FP, Strohmayer Lourencetti NM, Gomes PC, Ayusso GM, Dutra LA, Silva Bolzani VD, Regasini LO, Soares Mendes-Giannini MJ, Fusco-Almeida AM. Activity of 3'-hydroxychalcone against Cryptococcus gattii and toxicity, and efficacy in alternative animal models. Future Microbiol 2017; 12:1123-1134. [PMID: 28876122 DOI: 10.2217/fmb-2017-0062] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
AIM This work aimed to evaluate the activity of 3'-hydroxychalcone against Cryptococcus gattii in planktonic and biofilm forms and their toxicity using alternative animal models. MATERIALS & METHODS Minimum inhibitory concentration and minimum fungicide concentration were determined. Biofilm formation and the susceptibility tests were performed by the 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-5-[carbonyl(phenylamino)]-2H-tetrazolium hydroxide assay. Toxicity and efficacy were checked in Danio rerio and Galleria mellonella models. RESULTS The compound 3'-hydroxychalcone showed fungicidal activity against C. gattii in both planktonic and biofilm forms. The toxicity in zebrafish embryos revealed a low lethal concentration. In G. mellonella, the compound did not show antifungal activity and larvae toxicity. CONCLUSION Because of the activity of 3'-hydroxychalcone against C. gattii in vitro, molecular modifications should be made to improve efficacy and to reduce toxicity in vivo. [Formula: see text].
Collapse
Affiliation(s)
- Ana Cerrejón Palanco
- School of Pharmaceutical Sciences, UNESP - São Paulo State University, Araraquara, São Paulo, Brazil
| | | | | | - Fernanda Patrícia Gullo
- School of Pharmaceutical Sciences, UNESP - São Paulo State University, Araraquara, São Paulo, Brazil
| | | | - Paulo César Gomes
- School of Pharmaceutical Sciences, UNESP - São Paulo State University, Araraquara, São Paulo, Brazil
| | - Gabriela Miranda Ayusso
- Institute of Biosciences, Letters & Exact Sciences, UNESP - São José do Rio Preto, São Paulo, Brazil
| | | | | | - Luis Octávio Regasini
- Institute of Biosciences, Letters & Exact Sciences, UNESP - São José do Rio Preto, São Paulo, Brazil
| | | | - Ana Marisa Fusco-Almeida
- School of Pharmaceutical Sciences, UNESP - São Paulo State University, Araraquara, São Paulo, Brazil
| |
Collapse
|
2
|
Sardi JDCO, Gullo FP, Freires IA, Pitangui NDS, Segalla MP, Fusco-Almeida AM, Rosalen PL, Regasini LO, Mendes-Giannini MJS. Synthesis, antifungal activity of caffeic acid derivative esters, and their synergism with fluconazole and nystatin against Candida spp. Diagn Microbiol Infect Dis 2016; 86:387-391. [DOI: 10.1016/j.diagmicrobio.2016.08.002] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2016] [Revised: 07/11/2016] [Accepted: 08/05/2016] [Indexed: 12/16/2022]
|
3
|
Lima CS, Polaquini CR, Santos MBD, Gullo FP, Leite FS, Scorzoni L, Bolzani VDS, Mendes-Giannini MJS, Fusco-Almeida AM, Rezende AA, Regasini LO. Anti-Candida and anti-Cryptococcus evaluation of 15 non-alkaloidal compounds from Pterogyne nitens. Asian Pac J Trop Biomed 2016. [DOI: 10.1016/j.apjtb.2016.08.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
4
|
Sangalli-Leite F, Scorzoni L, Alves de Paula E Silva AC, da Silva JDF, de Oliveira HC, de Lacorte Singulani J, Gullo FP, Moraes da Silva R, Regasini LO, Siqueira da Silva DH, da Silva Bolzani V, Fusco-Almeida AM, Soares Mendes-Giannini MJ. Synergistic effect of pedalitin and amphotericin B against Cryptococcus neoformans by in vitro and in vivo evaluation. Int J Antimicrob Agents 2016; 48:504-511. [PMID: 27742203 DOI: 10.1016/j.ijantimicag.2016.07.025] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Revised: 07/13/2016] [Accepted: 07/30/2016] [Indexed: 11/26/2022]
Abstract
Cryptococcosis is an opportunistic fungal infection responsible for high morbidity and mortality in immunocompromised patients. Combination of antifungal substances is a promising way to increase the percentage of successful treatment. Pedalitin (PED) is a natural substance obtained from Pterogyne nitens. The aim of this study was to verify the efficacy of PED alone and in combination with amphotericin B (AmB) in vitro and in vivo against Cryptococcus spp. In the in vitro assay, minimum inhibitory concentrations (MICs) of 0.125 mg/L for AmB and 3.9 mg/L for PED were found when the substances were tested alone, whilst in the combination treatment the active concentration of both decreased, with MICs of 0.03 mg/L for AmB and 1 mg/L for PED. In the survival assay, fungal burden study and histopathological assays it was possible to study the efficacy of the substances alone and in combination. The efficacy of combination therapy was considered better than monotherapy as evaluated in a Galleria mellonella model and a murine model. Thus, the combination of PED and AmB is an interesting alternative for anticryptococcal fungal treatment. Moreover, a correlation was observed between the invertebrate and murine models for this antifungal treatment combination.
Collapse
Affiliation(s)
- Fernanda Sangalli-Leite
- Faculdade de Ciências Farmacêuticas de Araraquara, Universidade Estadual Paulista (UNESP), Departamento de Análises Clínicas, Laboratório de Micologia Clínica, Araraquara, Brazil
| | - Liliana Scorzoni
- Faculdade de Ciências Farmacêuticas de Araraquara, Universidade Estadual Paulista (UNESP), Departamento de Análises Clínicas, Laboratório de Micologia Clínica, Araraquara, Brazil
| | - Ana Carolina Alves de Paula E Silva
- Faculdade de Ciências Farmacêuticas de Araraquara, Universidade Estadual Paulista (UNESP), Departamento de Análises Clínicas, Laboratório de Micologia Clínica, Araraquara, Brazil
| | - Julhiany de Fátima da Silva
- Faculdade de Ciências Farmacêuticas de Araraquara, Universidade Estadual Paulista (UNESP), Departamento de Análises Clínicas, Laboratório de Micologia Clínica, Araraquara, Brazil
| | - Haroldo Cesar de Oliveira
- Faculdade de Ciências Farmacêuticas de Araraquara, Universidade Estadual Paulista (UNESP), Departamento de Análises Clínicas, Laboratório de Micologia Clínica, Araraquara, Brazil
| | - Junya de Lacorte Singulani
- Faculdade de Ciências Farmacêuticas de Araraquara, Universidade Estadual Paulista (UNESP), Departamento de Análises Clínicas, Laboratório de Micologia Clínica, Araraquara, Brazil
| | - Fernanda Patrícia Gullo
- Faculdade de Ciências Farmacêuticas de Araraquara, Universidade Estadual Paulista (UNESP), Departamento de Análises Clínicas, Laboratório de Micologia Clínica, Araraquara, Brazil
| | - Rosangela Moraes da Silva
- Faculdade de Ciências Farmacêuticas de Araraquara, Universidade Estadual Paulista (UNESP), Departamento de Análises Clínicas, Laboratório de Micologia Clínica, Araraquara, Brazil
| | | | | | | | - Ana Marisa Fusco-Almeida
- Faculdade de Ciências Farmacêuticas de Araraquara, Universidade Estadual Paulista (UNESP), Departamento de Análises Clínicas, Laboratório de Micologia Clínica, Araraquara, Brazil
| | - Maria José Soares Mendes-Giannini
- Faculdade de Ciências Farmacêuticas de Araraquara, Universidade Estadual Paulista (UNESP), Departamento de Análises Clínicas, Laboratório de Micologia Clínica, Araraquara, Brazil.
| |
Collapse
|
5
|
Soares LA, de Cássia Orlandi Sardi J, Gullo FP, de Souza Pitangui N, Scorzoni L, Leite FS, Giannini MJSM, Almeida AMF. Anti dermatophytic therapy--prospects for the discovery of new drugs from natural products. Braz J Microbiol 2014; 44:1035-41. [PMID: 24688490 PMCID: PMC3958166 DOI: 10.1590/s1517-83822014005000011] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2012] [Accepted: 04/04/2013] [Indexed: 12/11/2022] Open
Abstract
Millions of people and animals suffer from superficial infections caused by a group of highly specialized filamentous fungi, the dermatophytes, which only infect keratinized structures. With the appearance of AIDS, the incidence of dermatophytosis has increased. Current drug therapy used for these infections is often toxic, long-term, and expensive and has limited effectiveness; therefore, the discovery of new anti dermatophytic compounds is a necessity. Natural products have been the most productive source for new drug development. This paper provides a brief review of the current literature regarding the presence of dermatophytes in immunocompromised patients, drug resistance to conventional treatments and new anti dermatophytic treatments.
Collapse
Affiliation(s)
- Luciana Arantes Soares
- Departamento de Análises Clínicas, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista "Júlio Mesquita Filho", Araraquara, SP, Brazil
| | - Janaína de Cássia Orlandi Sardi
- Departamento de Análises Clínicas, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista "Júlio Mesquita Filho", Araraquara, SP, Brazil
| | - Fernanda Patrícia Gullo
- Departamento de Análises Clínicas, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista "Júlio Mesquita Filho", Araraquara, SP, Brazil
| | - Nayla de Souza Pitangui
- Departamento de Análises Clínicas, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista "Júlio Mesquita Filho", Araraquara, SP, Brazil
| | - Liliana Scorzoni
- Departamento de Análises Clínicas, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista "Júlio Mesquita Filho", Araraquara, SP, Brazil
| | - Fernanda Sangalli Leite
- Departamento de Análises Clínicas, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista "Júlio Mesquita Filho", Araraquara, SP, Brazil
| | - Maria José Soares Mendes Giannini
- Departamento de Análises Clínicas, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista "Júlio Mesquita Filho", Araraquara, SP, Brazil
| | - Ana Marisa Fusco Almeida
- Departamento de Análises Clínicas, Faculdade de Ciências Farmacêuticas, Universidade Estadual Paulista "Júlio Mesquita Filho", Araraquara, SP, Brazil
| |
Collapse
|
6
|
Gullo FP, Rossi SA, Sardi JDCO, Teodoro VLI, Mendes-Giannini MJS, Fusco-Almeida AM. Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment. Eur J Clin Microbiol Infect Dis 2013; 32:1377-91. [PMID: 24141976 DOI: 10.1007/s10096-013-1915-8] [Citation(s) in RCA: 83] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2013] [Accepted: 06/11/2013] [Indexed: 10/26/2022]
Abstract
Cryptococcosis is an important systemic mycosis and the third most prevalent disease in human immunodeficiency virus (HIV)-positive individuals. The incidence of cryptococcosis is high among the 25 million people with HIV/acquired immunodeficiency syndrome (AIDS), with recent estimates indicating that there are one million cases of cryptococcal meningitis globally per year in AIDS patients. In Cryptococcus neoformans, resistance to azoles may be associated with alterations in the target enzyme encoded by the gene ERG11, lanosterol 14α-demethylase. These alterations are obtained through mutations, or by overexpressing the gene encoding. In addition, C. gattii and C. neoformans present a heteroresistance phenotype, which may be related to increased virulence. Other species beyond C. neoformans and C. gattii, such as C. laurentii, have been diagnosed mainly in patients with immunosuppression. Infections of C. albidus have been isolated in cats and marine mammals. Recent evidence suggests that the majority of infections produced by this pathogen are associated with biofilm growth, which is also related with increased resistance to antifungal agents. Therefore, there is a great need to search for alternative antifungal agents for these fungi. The search for new molecules is currently occurring from nanoparticle drugs of plant peptide origin. This article presents a brief review of the literature regarding the epidemiology of cryptococcosis, as well as fungal resistance and new alternatives for treatment.
Collapse
Affiliation(s)
- F P Gullo
- Faculty of Pharmaceutical Sciences of Araraquara, Department of Clinical Analysis, Laboratory of Clinical Mycology, Universidade Estadual Paulista (UNESP), R. Expedicionários do Brasil, 1621, 14801-902, Araraquara, São Paulo, Brazil
| | | | | | | | | | | |
Collapse
|